| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Operating lease right-of-use and other long-term assets | 5,805 | 2,922 |
| Net cash used in operating activities | -181,331 | -100,704 |
| Maturities of short-term investments | 577,628 | 342,596 |
| Purchases of short-term investments | 521,813 | 383,314 |
| Purchases of property and equipment | 4,317 | 1,750 |
| Net cash provided by (used in) investing activities | 51,498 | -42,468 |
| Proceeds from issuance of stock under equity plans | 658 | 658 |
| Net cash provided by financing activities | 658 | 658 |
| Net increase (decrease) in cash and cash equivalents | -129,175 | -142,514 |
| Cash and cash equivalents at beginning of period | 224,462 | - |
| Cash and cash equivalents at end of period | 95,287 | - |
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)